Merck and Pfizer Collaborate with Dako
Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab
28-Sep-2015 -
As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the ...
avelumab
diagnostics
Merck
+1